Dr. Crystal Mackall, a leader in advancing cell and gene therapies for children's cancers, is the newest recipient of the Edward Netter Leadership Award. She has led numerous clinical trials treating children with sarcomas and brain cancers.
The Alliance for Cancer Gene Therapy Summit 2021 features key findings on translating CAR T-cell therapy success to complex solid tumors. Researchers share insights on evolving cell and gene regulatory processes, innovative science from the lab to the clinic, and tackling challenges in pancreatic cancer and glioblastoma.
A team led by Dr. Brian Brown is developing a CAR T-cell therapy that specifically targets immune-suppressing macrophages in tumors, clearing the way for other T cells to destroy cancer cells. The grant aims to advance this promising approach and bring new hope to patients with solid tumor cancers.
A Yale professor has received a $500,000 grant to develop a versatile and highly scalable strategy for treating pancreatic cancer. The technology, called MAEGI, targets multiple differences in cancer cells and activates multiple immune system responses.
Researchers at St. Jude Children's Research Hospital are exploring genetically engineered immune cells to attack pediatric sarcoma using a new ACGT grant. The approach aims to target not only cancer cells but also blood vessels supporting tumor growth, offering a promising new treatment for children with solid tumors.
A team of UPenn researchers is developing a new CAR T-cell gene therapy treatment for advanced metastatic prostate cancer, with the goal of overcoming resistance to current treatments. The ACGT-funded study aims to re-engineer T-cells to induce safe, long-term remission in patients.
Dr. Carl June is being honored by ACGT for his lifesaving CAR T-cell treatment, which was the first-ever FDA-approved gene therapy for cancer. The funding from ACGT sustained Dr. June's research, allowing it to continue and ultimately lead to promising treatments.
The Alliance for Cancer Gene Therapy (ACGT) is funding innovative clinical approaches to find gene therapy treatments for solid cancers. Recipients of the 2018 research grants include a team working on a vaccine for melanoma, an injectable genetic agent to program T cell receptors, and CAR T cell therapy for brain cancer.
Researchers found that combining oncolytic viruses and checkpoint inhibitors cured 60-90% of triple negative breast cancer in mice, while traditional treatments failed. The combination therapy showed promising results, but further research is needed to test its efficacy in humans.
Researchers at Alliance for Cancer Gene Therapy (ACGT) have received $1.3 million in critical funding to study immunotherapy and virotherapy for three deadly forms of cancer: glioblastoma, sarcoma, and ovarian cancer. The grants will support clinical trials to test innovative treatments using gene therapy.
The FDA has approved Kymriah, a CAR T gene therapy drug, for pediatric and young adult patients with ALL, marking a major milestone in cancer treatment. The therapy showed an exceptional 83 percent success remission rate in clinical trials.
The FDA advisory committee voted unanimously to recommend approval of Novartis' CAR-T therapy Tisagenlecleucel, demonstrating impressive results in hard-to-treat leukemia patients. ACGT's funding played a crucial role in advancing the pioneering treatment.
Dr. John Lahey has been honored with the first-ever ACGT Edward Netter Award for his contributions to cancer gene therapy. He is recognized for his strategic planning that grew student enrollment from 2,000 to nearly 10,000 students at Quinnipiac University.
Drs. Marco Gallo and Greg Delgoffe receive ACGT Young Investigator Grants to study glioblastoma and metastatic melanoma, focusing on gene therapy and T cell metabolism to boost immune responses against cancer.
Dr. Crystal Mackall receives $500,000 Clinical Translation Grant to study osteosarcoma and develop immunotherapy treatment options. The grant aims to improve outcomes for patients with this rare form of cancer.
Three researchers have received ACGT Young Investigator Grants to develop new treatments for leukemia/lymphoma, melanoma, and blood cancers. Dr. Yvonne Chen aims to improve CAR-T therapy, while Dr. Brent Hanks seeks to block the immune system's ability to destroy cancers using immunotherapy.
The Alliance has awarded grants to Dr. Andrew Davidoff, Dr. Thomas Griffith, and Dr. Jeffrey Bartlett to develop gene therapies targeting neuroblastoma, prostate cancer, and ovarian cancer. The research holds promise for improved quality of life and reduced side effects for cancer patients.